ANAB Stock Forecast: AnaptysBio, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering AnaptysBio, Inc. hold a median 12-month price target of $80 — +70.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 90 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores AnaptysBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (31): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ANAB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ANAB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +70.5% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | JP Morgan | Maintains | Overweight | $70 → $60 |
| 24 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $95 |
| 23 Sept 2026 | Leerink Partners | Maintains | Outperform | $90 → $81 |
| 25 Aug 2026 | TD Cowen | Maintains | Buy | $75 → $70 |
| 24 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $95 |
| 10 June 2026 | HC Wainwright & Co. | Assumes | Buy | $95 |
| 13 May 2026 | Barclays | Maintains | Overweight | — |
| 13 May 2026 | UBS | Maintains | Buy | — |
| 4 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 28 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 22 Apr 2026 | Barclays | Maintains | Overweight | — |
| 21 Apr 2026 | UBS | Maintains | Buy | — |
| 31 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 30 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2026 | UBS | Maintains | Buy | — |
| 12 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 9 Mar 2026 | Truist Securities | Maintains | Hold | — |
| 5 Mar 2026 | Stifel | Maintains | Buy | — |
| 4 Mar 2026 | Barclays | Maintains | Overweight | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ANAB.
This page is one stock. Monday covers all of them.
ANAB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ANAB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, AnaptysBio, Inc. returned +85.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ANAB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 7.3×
- Price / sales
- 23.4×
- Price / book
- 68.1×
- EV / EBITDA
- 168.5×
Cheaper than 81% of US stocks
Cheaper than 7% of US stocks
Cheaper than 1% of US stocks
Cheaper than 2% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −74.4%
- Gross margin
- —
- Operating margin
- 15.0%
- Net margin
- —
Higher than 6% of US stocks
Higher than 72% of US stocks
- Return on equity
- −35.6%
- Return on assets
- −3.6%
- Dividend yield
- —
Higher than 26% of US stocks
Higher than 34% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AnaptysBio, Inc. has a market value of $1.4B and an enterprise value of $1.5B.
Revenue in the twelve months to 31 Mar 2026: $232.4M. The latest quarter shrank 8.0% year on year.
Net income over the same four quarters: −$26.8M, a −11.5% net margin.
Diluted earnings per share, trailing twelve months: −$1.08.
Free cash flow in the twelve months to 31 Mar 2026: $4.4M, after $69K of capital spending.
AnaptysBio, Inc. spent $64.2M on share buybacks in the twelve months to 31 Mar 2026.
Trailing P/E: 7.3×; forward P/E: 10.8× — the forward figure prices analyst consensus estimates, not reported earnings.
AnaptysBio, Inc. employs 104 people — $2.2M of revenue per employee.
Data provided by Twelve Data
ANAB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ANAB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own AnaptysBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ANAB
What is the ANAB stock price forecast for 2026-2027?
The 8 Wall Street analysts covering AnaptysBio, Inc. have a median 12-month price target of $80, with estimates ranging from $60 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ANAB stock a buy right now?
Of the 8 analysts covering AnaptysBio, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AnaptysBio, Inc. 90 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ANAB?
As at 21 Nov 2026, AnaptysBio, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
Will ANAB stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +70.5% from the last close, and Ticker Nerd's factor model ranks AnaptysBio, Inc. 90 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ANAB stock forecast for 2030?
No analyst covering AnaptysBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $140 over the next 12 months.
How has ANAB stock performed over the past year?
AnaptysBio, Inc. returned +85.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does AnaptysBio, Inc. do?
AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfunction, with current work spanning clinical and preclinical candidates as well as royalty and collaboration assets.
About AnaptysBio, Inc.
AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfunction, with current work spanning clinical and preclinical candidates as well as royalty and collaboration assets. Its portfolio includes investigational therapies aimed at conditions such as rheumatoid arthritis, ulcerative colitis, atopic dermatitis, celiac disease, eosinophilic esophagitis, and generalized pustular psoriasis. The company also manages financial collaborations tied to partnered assets, reflecting a business model that combines internal drug development with externally partnered programs. Based in San Diego, California, AnaptysBio plays a role in the biotechnology market as a specialist in immune cell modulation and antibody therapeutics.
CEO Mr. Daniel R. Faga · 104 employees · United States · https://www.anaptysbio.com